Fate Therapeutics Partners with Janssen for iPSC-derived Immunotherapies
By Michelle Liu
Pharma Deals Review: Vol 2020 Issue 5 (Table of Contents)
Published: 21 May-2020
DOI: 10.3833/pdr.v2020.i5.2539 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
In a bid to bolster its immuno-oncology portfolio, Janssen Biotech has agreed to partner with Fate Therapeutics to develop induced pluripotent stem cell (iPSC)-derived product candidates for up to four tumour-associated antigen targets...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS